Section Arrow
Quote
IRWD.NASDAQ
- Ironwood Pharmaceuticals
Quotes are at least 15-min delayed:2026/05/19 04:08 EDT
Pre Market
Last
 --
-- (--)
Bid
3.09
Ask
3.86
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 3.5
-0.08 (-2.23%)
Day High 
3.61 
Prev. Close
3.58 
1-M High
4.88 
Volume 
2.44M 
Bid
3.09
Ask
3.86
Day Low
3.42 
Open
3.55 
1-M Low
3.47 
Market Cap 
589.32M 
Currency 美元 
P/E 5.65 
%Yield -- 
10-SMA 4.17 
20-SMA 4.15 
50-SMA 3.78 
52-W High 5.78 
52-W Low 0.55 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.62/1.33
Enterprise Value
984.19M
Balance Sheet
Book Value Per Share
-1.32
Cash Flow
Cash Flow Yield
0.19
Income Statement
Total Revenue
296.15M
Operating Revenue Per Share
2.60
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
SBFMSunshine Biopharma Inc0.51+0.2259+79.51%-- 
Pre Market 0.6115 +0.1015 +19.90%
HIMSHims & Hers Health22.29-2.76-11.02%-- 
Pre Market 22.385 +0.095 +0.43%
ESPREsperion Therapeutics3.13+0.01+0.32%-- 
Pre Market 3.12 -0.01 -0.32%
CGCCanopy Growth Corp0.9823-0.0577-5.55%-- 
Pre Market 0.99 +0.0077 +0.78%
VTRSViatris16.5+0.02+0.12%-- 
Pre Market 16.5 0 0.00%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.